Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Fragasso Financial Advisors Inc

Fragasso Financial Advisors Inc lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,979 shares of the medical research company’s stock after selling 146 shares during the quarter. Fragasso Financial Advisors Inc’s holdings in Thermo Fisher Scientific were worth $5,554,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Prentice Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific by 6.2% during the third quarter. Prentice Wealth Management LLC now owns 970 shares of the medical research company’s stock worth $600,000 after purchasing an additional 57 shares in the last quarter. Value Partners Investments Inc. lifted its stake in shares of Thermo Fisher Scientific by 1.2% in the third quarter. Value Partners Investments Inc. now owns 4,807 shares of the medical research company’s stock worth $2,973,000 after acquiring an additional 56 shares in the last quarter. Miracle Mile Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 2.7% in the third quarter. Miracle Mile Advisors LLC now owns 5,915 shares of the medical research company’s stock worth $3,659,000 after acquiring an additional 155 shares in the last quarter. Consilio Wealth Advisors LLC acquired a new position in shares of Thermo Fisher Scientific in the third quarter worth about $263,000. Finally, Chemistry Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific by 8.9% in the third quarter. Chemistry Wealth Management LLC now owns 587 shares of the medical research company’s stock worth $363,000 after acquiring an additional 48 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the sale, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the sale, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at $10,747,403.95. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Lisa P. Britt sold 3,624 shares of the business’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the sale, the vice president now directly owns 13,699 shares in the company, valued at approximately $8,397,760.98. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,084 shares of company stock valued at $14,094,292 in the last three months. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded up $0.24 during midday trading on Monday, hitting $598.85. 1,165,795 shares of the company’s stock were exchanged, compared to its average volume of 1,474,026. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. The stock’s 50 day moving average price is $609.46 and its 200-day moving average price is $582.80. The firm has a market cap of $228.76 billion, a P/E ratio of 38.39, a PEG ratio of 3.88 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.13 by $0.24. The business had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The business’s revenue was down 1.4% on a year-over-year basis. During the same period in the previous year, the firm posted $5.15 earnings per share. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be given a dividend of $0.39 per share. The ex-dividend date is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent analyst reports. Evercore ISI boosted their price target on Thermo Fisher Scientific from $605.00 to $630.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Barclays cut their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. Stifel Nicolaus boosted their price objective on Thermo Fisher Scientific from $615.00 to $680.00 and gave the company a “buy” rating in a report on Friday, September 20th. TD Cowen boosted their price objective on Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Finally, Raymond James boosted their price objective on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $653.72.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.